Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio's unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough.Trevi is headquartered in New Haven, CT.